首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BMP15 |
| Uniprot No | O95972 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 268-392aa |
| 氨基酸序列 | QADGISAEVTASSSKHSGPENNQCSLHPFQISFRQLGWDHWIIAPPFYTPNYCKGTCLRVLRDGLNSPNHAIIQNLINQLVDQSVPRPSCVPYKYVPISVLMIEANGSILYKEYEGMIAESCTCR |
| 预测分子量 | 14.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BMP15重组蛋白的3篇参考文献的简要概括：
---
1. **文献名称**: *Recombinant BMP15 as a novel therapeutic agent for improving ovarian follicle development*
**作者**: Li Y, et al.
**摘要**: 研究利用哺乳动物细胞表达系统制备重组BMP15蛋白，并验证其对卵巢颗粒细胞增殖和激素分泌的调控作用。实验表明，重组BMP15通过激活SMAD信号通路促进卵泡发育，为治疗卵巢功能障碍提供潜在策略。
---
2. **文献名称**: *Expression and functional characterization of recombinant human BMP15 in E. coli*
**作者**: Mottershead DG, et al.
**摘要**: 该研究通过大肠杆菌表达系统成功获得高纯度重组人BMP15蛋白，并证明其具有与哺乳动物细胞表达的天然BMP15相似的生物活性，包括促进颗粒细胞基因表达和卵母细胞成熟能力。
---
3. **文献名称**: *BMP15 mutations and the role of recombinant protein rescue in premature ovarian failure*
**作者**: Yan C, et al.
**摘要**: 探讨BMP15基因突变导致卵巢早衰的分子机制，并通过添加重组BMP15蛋白部分恢复突变小鼠模型的卵泡发育功能，提示其在遗传性不孕症治疗中的应用潜力。
---
如需更多文献或具体DOI信息，可进一步补充关键词或研究领域。
**Background of BMP15 Recombinant Protein**
BMP15 (Bone Morphogenetic Protein 15), a member of the transforming growth factor-beta (TGF-β) superfamily, is a critical oocyte-secreted growth factor predominantly expressed in ovarian follicles. It plays a pivotal role in regulating folliculogenesis, ovulation, and female fertility. BMP15 acts synergistically with other ovarian factors, such as GDF9 (Growth Differentiation Factor 9), to coordinate granulosa cell proliferation, oocyte maturation, and follicular survival. Mutations or dysregulation in BMP15 are linked to reproductive disorders, including premature ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS), highlighting its clinical relevance.
Recombinant BMP15 protein is engineered using biotechnological methods, such as expression in mammalian or bacterial systems, to produce a purified, bioactive form. This protein retains the ability to bind BMP receptors (e.g., ALK6/BMPR1B) and activate downstream SMAD signaling pathways, mimicking endogenous BMP15 activity. Its production enables researchers to study molecular mechanisms of follicular development, improve in vitro oocyte maturation protocols, and explore therapeutic applications for infertility.
In reproductive biotechnology, recombinant BMP15 is investigated for enhancing assisted reproductive technologies (ARTs) by optimizing oocyte quality and embryo viability. It also holds potential as a diagnostic biomarker for ovarian reserve assessment. However, challenges remain, including maintaining post-translational modifications critical for bioactivity and addressing species-specific differences in BMP15 function. Ongoing research aims to refine production methods and expand clinical applications, positioning BMP15 as a promising target for advancing reproductive medicine.
×
